SCHEMBL3545768

SCHEMBL3545768

CS(=O)(=O)N1CCN(c2ccc(NC(=O)C(=O)O)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.55
MAPT P10636 8/20 0.49
KDM4E B2RXH2 1/20 0.49
RAB9A P51151 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 2/20 0.46
POLB P06746 2/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 1/20 0.45
GLA P06280 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13009506 0.88 DGAT1 (0.51) DGAT1MAPTKDM4ERAB9AL3MBTL1
SCHEMBL23245955 0.82 DGAT1 (0.50) DGAT1MAPTKDM4ERAB9AL3MBTL1
SCHEMBL29618345 0.82 DGAT1 (0.50) DGAT1MAPTKDM4ERAB9AL3MBTL1
SCHEMBL20425015 0.77 RORC (0.49) DGAT1KDM4ERAB9AL3MBTL1ALDH1A1
SCHEMBL29883957 0.76 LMNA (0.51) DGAT1MAPTKDM4ERAB9AALDH1A1
SCHEMBL3934328 0.76 ME2 (0.49) KDM4ERAB9AL3MBTL1ALDH1A1MEN1
SCHEMBL3546608 0.75 DGAT1 (0.75) DGAT1
SCHEMBL4805468 0.74 RAB9A (0.67) MAPTKDM4ERAB9AL3MBTL1MEN1
SCHEMBL20425003 0.74 NPC1 (0.45) DGAT1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL15450910 0.74 GPR119 (0.58) KDM4ERAB9AALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 DGAT1 1/4885MAPT 2115/4885KDM4E 3511/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 DGAT1 1/4885MAPT 1986/4885KDM4E 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.